Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
64. (WO2014043421) USE OF MARKERS IN THE IDENTIFICATION OF CARDIOTOXIC AGENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/043421 International Application No.: PCT/US2013/059559
Publication Date: 20.03.2014 International Filing Date: 12.09.2013
IPC:
G01N 33/567 (2006.01) ,G01N 33/53 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
566
using specific carrier or receptor proteins as ligand binding reagent
567
utilising isolate of tissue or organ as binding agent
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
Applicants:
BERG LLC [US/US]; 1845 Elm Hill Pike Nashville, TN 37210, US
Inventors:
NARAIN, Niven, Rajin; US
SARANGARAJAN, Rangaprasad; US
VISHNUDAS, Vivek, K.; US
KIEBISH, Michael, Andrew; US
Agent:
MELLO, Jill, Ann; McCarter & English, LLP 265 Franklin Street Boston, MA 02110, US
Priority Data:
61/700,32712.09.2012US
61/706,61127.09.2012US
61/727,10415.11.2012US
61/727,11516.11.2012US
61/732,10530.11.2012US
Title (EN) USE OF MARKERS IN THE IDENTIFICATION OF CARDIOTOXIC AGENTS
(FR) UTILISATION DE MARQUEURS DANS L'IDENTIFICATION D'AGENTS CARDIOTOXIQUES ET DANS LE DIAGNOSTIC ET LA SURVEILLANCE D'UNE MYOCARDIOPATHIE ET D'UNE MALADIE CARDIOVASCULAIRE
Abstract:
(EN) The invention provides methods for the diagnosis and prognosis of cardiovascular disease, and for monitoring of the treatment of cardiovascular disease, including heart failure and cardiomyopathy. The invention further provides methods for identifying an agent for treating cardiomyopathy or heart failure, for identifying a cardiotoxic agent, and for identifying a rescue agent to reduce or prevent drug-induced toxicity, by using one or more biomarkers selelcted from the group consisting of CCDC47, HMOX1, PTX3, PAI1, IL27, IGFBP7, Emmprin, CFL2, EDIL3, NUCB1, PE D18:0-20:3/D18:1-20:2/D16:0-22:3; PE D18:0-22:5/D18:1-22:4; PE D16:1-22:6; PE P18:1-18:1/P18:0-18:2/P16:0-20:2; LPC 20:3; and PC-LI-183-D18:22-22:6, or any of the other biomarkers provided herein. The invention further provides kits for practicing the methods of the invention.
(FR) L'invention concerne des méthodes de diagnostic et de pronostic d'une maladie cardiovasculaire et de surveillance du traitement d'une maladie cardiovasculaire, comprenant une insuffisance cardiaque et une myocardiopathie. L'invention concerne en outre des procédés d'identification d'un agent pour le traitement d'une myocardiopathie ou d'une insuffisance cardiaque, pour l'identification d'un agent cardiotoxique et pour l'identification d'un agent sauveur pour réduire ou prévenir une toxicité induite par un médicament, par l'utilisation d'un ou de plusieurs biomarqueurs choisis dans le groupe constitué par CCDC47, HMOX1, PTX3, PAI1, IL27, IGFBP7, Emmprin, CFL2, EDIL3, NUCB1, PE D18:0-20:3/D18:1-20:2/D16:0-22:3; PE D18:0-22:5/D18:1-22:4; PE D16:1-22:6; PE P18:1-18:1/P18:0-18:2/P16:0-20:2; LPC 20:3; et PC-LI-183-D18:22-22:6 ; ou n'importe lequel des autres biomarqueurs présentés ici. L'invention concerne en outre des nécessaires pour la mise en œuvre des procédés de l'invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)